Mounjaro (Tirzepatīds) ir progresīva svara kontroles ārstēšana, kas imitē divus dabiskus hormonus jūsu ķermenī: GLP-1 un GIP. Darbojoties pa šiem dažādajiem ceļiem, Mounjaro palīdz cilvēkiem kontrolēt svaru un uzlabot vielmaiņas veselību, lietojot to kopā ar veselīgu uzturu un regulāru fizisko aktivitāti.

Once a week one injection.

Active Ingredient Tirzepatide Each pre-filled pen contains 0.5 ml of solution. The medication is available in the following strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Other Ingredients (Excipients) Disodium hydrogen phosphate heptahydrate (E339) Sodium chloride Sodium hydroxide (for pH adjustment) Concentrated hydrochloric acid (for pH adjustment) Water for injections

Gastrointestinal problems (nausea, vomiting, diarrhoea, constipation), a potential risk of hypoglycaemia (especially when used with other diabetes medications), injection site reactions, and other effects depending on the individual’s health status and other medicines taken.

When using Mounjaro (tirzepatide), it is important to take certain precautions. Be alert to severe abdominal pain, which may indicate pancreatitis. Monitor blood sugar levels closely, as there is a risk of hypoglycaemia when Mounjaro is used together with other diabetes medications. Report any changes in urination, which could signal kidney problems, and seek medical advice promptly if you experience persistent digestive symptoms such as vomiting or diarrhoea.

It is also essential to inform your doctor of any personal or family history of thyroid cancer, as studies in rodents have linked medicines similar to Mounjaro to thyroid-related issues. Watch for signs of allergic reactions, and if you are pregnant or breastfeeding, consult your healthcare professional about potential risks before using this medication.